YahooOctober 24, 2026 at 7:39 AM NY3 Days Ago
Eli Lilly's Next-Generation Ovarian Cancer Drug Shows 79% Response Rate, 100% Disease Control In New Data
The results come as Lilly continues to test Sofe-M in different types of ovarian cancer, with multiple Phase 3 trials now underway.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
